Miguel Ángel Luna

Miguel Ángel Luna

Auto-generated profile, based on publicly available information

Miguel Ángel Luna

B-ARGO Group, Medical Oncology Department, ICO Badalona, Germans Trias I Pujol Institute, Badalona, Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2017 in Microsurgery
Verified
Journal Article
Closed access
PDF file
CLCristian carrasco lopez
Cristian carrasco lopez
JJJoan Francesc Julián
Joan Francesc Julián
JVJordi Vilà
Jordi Vilà
MTMiguel Angel Luna Tomás
Miguel Angel Luna Tomás
JLJordi Navinés López
Jordi Navinés López
CHCarmen Higueras‐Suñe
Carmen Higueras‐Suñe

16 January 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
MVMaría Jesus Vidal
María Jesus Vidal
CFClaudette Falato
Claudette Falato
TPTomas Pascual
Tomas Pascual
RSRodrigo Sánchez-Bayona
Rodrigo Sánchez-Bayona
MMMontserrat Muñoz-Mateu
Montserrat Muñoz-Mateu
Meritxell BelletMeritxell Bellet
Meritxell Bellet
Purpose: Elacestrant has shown significantly prolonged progression-free survival compared with standard-of-care endocrine therapy in estrogen receptor–positive (ER-positive), HER2-negative metastatic breast cancer, whereas potential benefit in early-stage disease requires further exploration. The SOLTI-ELIPSE window-of-opportunity trial investigated the biological changes induced by a short course of preoperative elacestrant in postmenopausal women with early breast cancer. Patients and Methods: Eligible patients with untreated T1c (≥1.5 cm)-T3, N0, ER-positive/HER2-negative breast cancer with locally assessed Ki67 ≥10% received elacestrant at a daily dose of 345 mg for 4 weeks. The primary efficacy endpoint was complete cell cycle arrest, defined as Ki67 ≤2.7%, on day 28. Results: Overall, 22 patients were evaluable for the primary endpoint. Elacestrant was associated with a complete cell cycle arrest rate of 27.3% and a statistically significant Ki67 geometric mean change of −52.9% (P = 0.007; 95% confidence interval, −67.4 to −32.1). Notably, the treatment with elacestrant led to a shift toward a more endocrine-sensitive and less proliferative tumor phenotype based on PAM50-based gene signatures. Elacestrant increased the expression of immune-response genes (GZMB, CD4, and CD8A) and suppressed proliferation and estrogen-signaling genes (MKI67, ESR1, and AR). These biological changes were independent of the levels of Ki67 suppression on day 28. The most common adverse events were grade 1 anemia (21.7%), hot flushes (8.7%), constipation (8.7%), and abdominal pain (8.7%). One patient experienced a grade 3 cutaneous rash, leading to treatment discontinuation. No other serious adverse events were reported. Conclusions: Preoperative treatment with elacestrant in early breast cancer demonstrated relevant biological and molecular responses and exhibited a manageable safety profile. These findings support further investigation of elacestrant in the early setting.

1 October 2013 in The Breast
Verified
Journal Article
Closed access
MSMontserrat Solá
Montserrat Solá
MMMireia Margelí
Mireia Margelí
ECEva Castellá
Eva Castellá
BCBeatriz Cirauqui
Beatriz Cirauqui
AMAntonio Mariscal
Antonio Mariscal
MFManuel Fraile
Manuel Fraile

22 May 2015 in Breast Care
Verified
Journal Article
Closed access
VQVanesa Quiroga-García
Vanesa Quiroga-García
BCBeatriz Cirauqui-Cirauqui
Beatriz Cirauqui-Cirauqui
CBCristina Bugés-Sánchez
Cristina Bugés-Sánchez
MLMiguel Ángel Luna-Tomás
Miguel Ángel Luna-Tomás
ECEva María Castellà-Fernández
Eva María Castellà-Fernández
MMMireia Margelí-Vila
Mireia Margelí-Vila
Background: Treatment with aromatase inhibitors (AIs) followed by surgery is often recommended for women with locoregional hormone-sensitive breast cancer. However, no study has compared the efficacy of AIs alone versus AIs followed by surgery. Methods: 33 postmenopausal breast cancer patients were treated with primary hormone therapy. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor type 2 receptor (HER2) expression levels were analyzed by immunohistochemistry. After hormone therapy, eligible patients underwent surgery, and those who were not candidates for surgery continued on hormone therapy. We retrospectively analyzed time to progression, overall survival, response, and impact of surgery on outcome. Results: All patients were ER+. HER2 was successfully analyzed in 30 patients, all of whom were HER2-. The median time to progression was 94 months, and the median overall survival was not reached, while the mean overall survival was 123 months. The overall response rate was 63.6%, with 9.1% complete responses. No significant differences in time to progression or survival were observed between patients who underwent surgery and those who did not. Conclusions: Primary hormone therapy with AIs is effective in elderly breast cancer patients with high levels of hormone receptors and may provide a feasible and tolerable alternative to surgery in selected hormone-sensitive breast cancer patients.

1 April 2018 in The Breast
Verified
Journal Article
Closed access
MLM.A. Luna-Tomás
M.A. Luna-Tomás
MSM. Solà-Suárez
M. Solà-Suárez
AMA. Mariscal-Martínez
A. Mariscal-Martínez
ECE. Castellà-Fernández
E. Castellà-Fernández
SMS. Martínez-Román
S. Martínez-Román
JJJoan Francesc Julián
Joan Francesc Julián

1 March 2020 in Surgical Oncology
Verified
Journal Article
Closed access
LBLidia Blay
Lidia Blay
MPManel Cremades Pérez
Manel Cremades Pérez
Jordi Navinés-LópezJordi Navinés-López
Jordi Navinés-López
IMIciar Pascual Miguel
Iciar Pascual Miguel
CLCristian carrasco lopez
Cristian carrasco lopez
JJJoan Francesc Julián
Joan Francesc Julián